Swiss pharmaceutical giant Roche has announced that it has received approval from European Union health regulators to market a new blood test designed for the early diagnosis of Alzheimer’s disease.
The test, named Elecsys pTau217, was developed in collaboration with the American laboratory Eli Lilly. It measures protein abnormalities in the blood that lead to neurodegenerative diseases. According to the company, this blood test is much simpler to use than the existing method, which involves collecting cerebrospinal fluid (CSF) via a lumbar puncture. The test has already received the “CE” mark, signifying that it fully complies with EU health and safety standards.
Matt Sause, CEO of Roche Diagnostics, noted that the launch of this test is a significant step toward achieving diagnosis at a much earlier stage. He stated that implementing the test into routine practice will allow physicians to intervene in a timely manner, which is critically important for patients and their families.
Alzheimer’s disease is the most common form of dementia; however, according to Roche’s data, it currently takes an average of three and a half years to diagnose. The new technology aims to significantly reduce this timeframe.
The emergence of this test represents a true revolution in medicine, as it simplifies Alzheimer’s diagnostics from complex and painful procedures, such as spinal fluid sampling, to a routine blood analysis. Until now, a test of such precision was not available for mass marketing. The Elecsys pTau217 can detect signs of the disease in the blood years before the first symptoms appear, allowing doctors to begin treatment at a stage when brain damage is still minimal.
